Spots Global Cancer Trial Database for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Official Title: Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Study ID: NCT05956821
Interventions
Study Description
Brief Summary: This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Detailed Description:
Keywords
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Jackson Memorial Hospital, Miami, Florida, United States
Contact Details
Name: Heather McCrea, MD
Affiliation: University of Miami
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
